(August 11 18:12) Forbes.com
As CMS pursues a National Coverage Determination for monoclonal antibodies targeting amyloid beta plaque, such as Aduhelm, this could result in a boon for brain scans - such as Amyvid, an amyloid PET imaging scan - that evaluate amyloid beta neuritic plaque density.
You can find the original article
here